What happened
Iradimed Corporation (NASDAQ: IRMD) reported third-quarter 2026 revenue of $24.2 million, up 14% from $21.2 million a year earlier. It also narrowed its 2026 outlook.
GAAP diluted earnings per share were $0.51, up $0.08 or 17% from $0.43 a year earlier. Non-GAAP diluted EPS was $0.55 against $0.47. Revenue rose 18% from the second quarter, when GAAP EPS was $0.41.
President and Chief Executive Officer Roger Susi tied the record revenue to the continued launch of the 3870 MR IV pump. Bookings also set records, including a 45% year-over-year rise in domestic pump channels booked. Over 70% of pump bookings were for a quad stack of four pumps on one IV pole. The board declared a regular quarterly dividend of $0.20 per share.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Q3 2026 revenue | $24.2 million | from $21.2 million, +14% | SEC 8-K Exhibit 99.1 |
| Q3 2026 GAAP diluted EPS | $0.51 | from $0.43, +17% | SEC 8-K Exhibit 99.1 |
| Q3 2026 non-GAAP diluted EPS | $0.55 | from $0.47, +17% | SEC 8-K Exhibit 99.1 |
| Q3 2026 gross profit margin | 76% | from 78%, -2 percentage points | SEC 8-K Exhibit 99.1 |
| Q4 2026 revenue guidance, low end, versus Q3 revenue | $25.0 million | +3.3% | Calculated from SEC 8-K |
| Full-year 2026 revenue guidance | $91.6 million to $93.1 million | SEC 8-K Exhibit 99.1 |
Read more: Iradimed (IRMD) company research
Why it matters
Disposables and monitors both grew. Disposables revenue rose to $5.0 million from $4.1 million a year earlier. Vital signs monitor revenue rose to $8.0 million from $6.9 million. Pump system revenue was $8.7 million against $8.3 million.
Fourth-quarter revenue guidance of $25.0 million to $26.5 million starts 3.3% above third-quarter revenue, by OptimistFi's calculation.
The full-year outlook lowers its upper end. Revenue guidance is now $91.6 million to $93.1 million, from $91.0 million to $96.0 million. GAAP EPS guidance is $1.90 to $1.94, from $1.90 to $2.05. Gross margin was 76% against 78% a year earlier, though the company said it improved from the prior quarter as expected.
OptimistFi has argued that differentiated pumps and a growing installed base can lift cash flow and EPS. Record bookings and rising disposables fit that view. The lower margin and the cut to the top of guidance temper it.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Iradimed scheduled a conference call for 11:00 a.m. Eastern on Oct. 30 to discuss the quarter.
Fourth-quarter GAAP EPS guidance is $0.53 to $0.57. Hitting that range with gross margin improving again would back the case. A miss would reinforce the margin concern. The dividend is payable Nov. 27 to holders of record on Nov. 13.
More from OptimistFi
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
Sources
- Iradimed Corporation third-quarter 2026 earnings release (SEC EDGAR 8-K, Exhibit 99.1) — Press release dated Oct. 30, 2026 with results, guidance, dividend declaration and financial tables.
Explore OptimistFi research on Iradimed Corporation: https://optimistfi.com/stocks/IRMD
Browse Iradimed Corporation company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Iradimed Corporation company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
